Medtronic Infuse Lawsuit Appealed to U.S. Supreme Court Over Off-Label Marketing

The U.S. Supreme Court is being asking to review whether Medtronic is still able to seek immunity from failure to warn claims under federal preemption due to FDA approval of their Infuse bone growth product, even if the manufacturer engaged in off-label promotion for uses that were never reviewed or determined to be safe by federal regulators.

A petition for certiorari was filed earlier this month in a product liability lawsuit over complications following Medtronic Infuse surgery, seeking to overturn a decision by the U.S. Court of Appeals for the 10th Circuit, which found that claims brought by Patricia Caplinger were preempted by the FDA’s approval of the bone growth device and its label warnings.

Caplinger argues that preemption does not apply in her case, because Medtronic promoted their Infuse product for uses that were never reviewed or approved by the FDA, and those same “off-label” applications were how Infuse was used in her case.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Medtronic Infuse is a newer type of bio-engineered bone graft product that has been promoted as an alternative to traditional spinal fusions, where bone is harvested from another area of the body or used from a cadaver.

The FDA only approved Infuse recombinant human bone morphogenetic protein (rhBMP-2) for limited use during spinal fusion procedures where the lumbar spine is approached through the front and the product is applied to an absorbable collagen sponge that is placed within an “LT-Cage” that is implanted to encourage bone growth and fuse the gaps between the vertebrae. However, the product has been widely used off-label during other types of spinal surgery, and many users have reported suffering catastrophic complications due to excessive bone growth around the spine.

Hundreds of Medtronic Infuse lawsuits have been filed against the manufacturer, alleging that it failed to provide adequate warnings about the risk of complications and illegally promoted the device for uses that it never established were safe or effective.

Caplinger underwent lumbar spinal fusion surgery in August 2010, when Infuse was implanted via a posterior approach, which is not approved by the FDA. Months after the spinal surgery, Caplinger began to develop foot-drop in her right leg, which was later linked to excessive bone growth caused by Infuse. This led to a tear in her anterior cruciate ligament and knee surgery in 2011.

Later in 2011, examinations found that “exuberant” bone growth around Caplinger’s lumbar spine, allegedly caused by the Infuse implant. She had to have revision surgery to have the implant removed.

The U.S. Court of Appeals for the 10th Circuit dismissed Caplinger’s case, finding that the failure-to-warn claims are preempted by federal law since Infuse was approved by the FDA.

If the U.S. Supreme Court grants cert in the case, their decision could have wide-ranging implications far beyond Caplinger’s case, potentially impacting product liability lawsuits involving other types of medical devices that were promoted off-label.


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Management of Ozempic Lawsuit Pretrial Proceedings To Be Reassigned Following Death of MDL Judge
Management of Ozempic Lawsuit Pretrial Proceedings To Be Reassigned Following Death of MDL Judge (Posted today)

The judge overseeing Ozempic lawsuits consolidated in federal court has died, requiring a new judge to be assigned to oversee coordinated pretrial proceedings over claims the diabetes drug and similar medications caused stomach paralysis and other intestinal complications.

Baby Food Injury Lawyers Appointed To Leadership Roles in Autism, ADHD Lawsuits Over Heavy Metal Contamination
Baby Food Injury Lawyers Appointed To Leadership Roles in Autism, ADHD Lawsuits Over Heavy Metal Contamination (Posted 2 days ago)

A group of 19 plaintiffs' lawyers have been appointed to serve in various leadership position during the consolidated pretrial proceedings for all baby food injury lawsuits, taking actions that benefit all families pursuing claims for children diagnosed with autism, ADHD or other developmental problems from toxic heavy metals found in many popular products sold in recent years.